Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

Effects of Inulin-Based Prebiotics on Gut Microbiota After Rectal Cancer Surgery (PUMCH-1-YSY)

14 de noviembre de 2026 actualizado por: Guole Lin, Peking Union Medical College Hospital

Effects of Inulin-Based Compound Prebiotics on Postoperative Gut Microbiota Dysbiosis in Patients With Rectal Cancer: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial

Postoperative gut microbiota dysbiosis is a common clinical concern in patients undergoing rectal cancer surgery and may contribute to gastrointestinal dysfunction and postoperative complications. Inulin-based compound prebiotics may help maintain intestinal microbial balance by promoting beneficial bacteria and modulating gut microbial composition. However, their efficacy and safety in preventing postoperative gut microbiota dysbiosis in patients with rectal cancer remain to be established.

This study is a multicenter, randomized, double-blind, placebo-controlled, three-arm clinical trial designed to evaluate the efficacy and safety of inulin-based compound prebiotics in preventing gut microbiota dysbiosis following radical rectal cancer surgery and to assess their effects on gut microbiota composition.

A total of 261 adult patients with histologically confirmed rectal adenocarcinoma undergoing laparoscopic radical rectal cancer surgery with a protective intestinal stoma will be enrolled at three study centers. Eligible participants will be randomly assigned in a 1:1:1 ratio to one of three groups: (1) inulin-based compound prebiotics combined with probiotics, (2) probiotics combined with placebo, or (3) placebo alone. Study interventions will be administered from postoperative day 1 through day 5.

The primary outcome is the incidence of gut microbiota dysbiosis within five days after surgery. Secondary outcomes include changes in gut microbiota composition and diversity, inflammatory markers, and fecal short-chain fatty acid levels. Gut microbiota will be assessed using 16S rRNA gene sequencing and metagenomic sequencing. Safety will be evaluated through the monitoring and recording of adverse events throughout the intervention period.

This study aims to provide clinical evidence regarding the efficacy and safety of inulin-based compound prebiotics for preventing postoperative gut microbiota dysbiosis and their potential role in modulating intestinal microbial homeostasis in patients undergoing rectal cancer surgery.

Descripción general del estudio

Tipo de estudio

Intervencionista

Inscripción (Estimado)

261

Fase

  • No aplica

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Estudio Contacto

  • Nombre: Guole Lin
  • Número de teléfono: 010-13001081483
  • Correo electrónico: linguole@126.com

Ubicaciones de estudio

      • Beijing, Porcelana, 100730
        • Peking Union Medical College Hospital
        • Contacto:
      • Beijing, Porcelana, 100000
        • Beijing Friendship Hospital, Capital Medical University
        • Contacto:
      • Beijing, Porcelana, 100007
        • Beijing Sixth Hospital
        • Contacto:
          • Yi An
          • Número de teléfono: 010-13621224452

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

18 años y mayores (Adulto, Adulto Mayor)

Acepta Voluntarios Saludables

No

Géneros elegibles para el estudio

Todos

Descripción

Inclusion Criteria:

  1. Adults aged 18 years or older.
  2. Eastern Cooperative Oncology Group (ECOG) performance status of 0-3 before surgery.
  3. Histologically confirmed rectal adenocarcinoma diagnosed by endoscopic biopsy, with the lower margin of the tumor located ≤12 cm from the anal verge.
  4. Undergoing laparoscopic radical rectal cancer surgery with a protective intestinal stoma.
  5. Willing and able to provide written informed consent, understand and comply with study requirements and procedures, and not currently participating in another clinical study considered by the investigator to conflict with this study.

Exclusion Criteria:

  1. Known intolerance to inulin or prebiotics.
  2. History of severe irritable bowel syndrome (IBS) or inflammatory bowel disease (IBD).
  3. Presence of distant metastases, including liver or lung metastases.
  4. Severe intestinal obstruction, gastrointestinal perforation, gastrointestinal bleeding, or other conditions requiring emergency treatment.
  5. Undergoing open radical rectal cancer surgery or conversion from laparoscopic to open surgery.
  6. Use of antibiotics (excluding planned perioperative antibiotic prophylaxis), prebiotics, probiotics, synbiotic products, or immunosuppressive agents within one month before surgery.
  7. Severe cardiovascular, cerebrovascular, hepatic, renal, pulmonary, or hematopoietic system diseases.
  8. Pregnant or breastfeeding women.
  9. Any other condition that, in the investigator's judgment, makes the participant unsuitable for inclusion in the study.

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Prevención
  • Asignación: Aleatorizado
  • Modelo Intervencionista: Asignación paralela
  • Enmascaramiento: Doble

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Experimental: Inulin-Based Compound Prebiotics Plus Probiotics

Participants in this group will receive oral inulin-based compound prebiotics (4 g twice daily on postoperative day 1, followed by 8 g twice daily on postoperative days 2-5), combined with compound Lactobacillus enteric-coated capsules (0.66 g three times daily) and a triple viable Bifidobacterium preparation (0.42 g three times daily). All interventions will be administered from postoperative day 1 through day 5.

An oral inulin-based compound prebiotic supplement containing inulin (62.5%), polydextrose (10%), allulose (10%), isomaltooligosaccharides (7.88%), tagatose (7.75%), hyaluronic acid (1.25%), and chitosan oligosaccharides (0.63%). Participants will receive 4 g orally twice daily on postoperative day 1, followed by 8 g orally twice daily on postoperative days 2-5. The intervention will be administered in combination with probiotic preparations in the experimental group.

An oral probiotic preparation containing two strains of Lactobacillus rhamnosus and Enterococcus faecium. Participants will receive 0.66 g orally three times daily from postoperative day 1 through day 5. This intervention will be administered in both the inulin-based compound prebiotics plus probiotics group and the probiotics plus placebo group.

An oral probiotic preparation containing Bifidobacterium longum, Lactobacillus acidophilus, and Enterococcus faecalis. Participants will receive 0.42 g orally three times daily from postoperative day 1 through day 5. This intervention will be administered in both the inulin-based compound prebiotics plus probiotics group and the probiotics plus placebo group.

Comparador activo: Probiotics Plus Placebo

Participants in this group will receive compound Lactobacillus enteric-coated capsules (0.66 g orally three times daily) and a triple viable Bifidobacterium preparation (0.42 g orally three times daily), combined with maltodextrin placebo administered at the same dosage and schedule as the inulin-based compound prebiotics group. All interventions will be administered from postoperative day 1 through day 5.

An oral probiotic preparation containing two strains of Lactobacillus rhamnosus and Enterococcus faecium. Participants will receive 0.66 g orally three times daily from postoperative day 1 through day 5. This intervention will be administered in both the inulin-based compound prebiotics plus probiotics group and the probiotics plus placebo group.

An oral probiotic preparation containing Bifidobacterium longum, Lactobacillus acidophilus, and Enterococcus faecalis. Participants will receive 0.42 g orally three times daily from postoperative day 1 through day 5. This intervention will be administered in both the inulin-based compound prebiotics plus probiotics group and the probiotics plus placebo group.

Maltodextrin will be used as a placebo to match the inulin-based compound prebiotic supplement and probiotic preparations. For the prebiotic-matched placebo, participants will receive 4 g orally twice daily on postoperative day 1, followed by 8 g twice daily on postoperative days 2-5. For the probiotic-matched placebo, participants will receive maltodextrin at doses of 0.66 g and 0.42 g, each administered orally three times daily from postoperative day 1 through day 5. The probiotics plus placebo group will receive the prebiotic-matched placebo, while the placebo comparator group will receive both placebo regimens.

Comparador de placebos: Placebo

Participants in this group will receive oral maltodextrin placebo (4 g twice daily on postoperative day 1, followed by 8 g twice daily on postoperative days 2-5), together with additional maltodextrin placebo (0.66 g and 0.42 g, each administered orally three times daily) to match the probiotic preparations used in the other groups. All interventions will be administered from postoperative day 1 through day 5.

Maltodextrin will be used as a placebo to match the inulin-based compound prebiotic supplement and probiotic preparations. For the prebiotic-matched placebo, participants will receive 4 g orally twice daily on postoperative day 1, followed by 8 g twice daily on postoperative days 2-5. For the probiotic-matched placebo, participants will receive maltodextrin at doses of 0.66 g and 0.42 g, each administered orally three times daily from postoperative day 1 through day 5. The probiotics plus placebo group will receive the prebiotic-matched placebo, while the placebo comparator group will receive both placebo regimens.

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Incidence of Postoperative Gut Microbiota Dysbiosis
Periodo de tiempo: Postoperative days 1-5

The primary outcome is the proportion of participants who develop gut microbiota dysbiosis within five days following laparoscopic radical rectal cancer surgery with a protective intestinal stoma. Postoperative gut microbiota dysbiosis will be assessed based on clinical manifestations, including abdominal distension, diarrhea or increased stoma output, abdominal pain, fever, nausea, and vomiting, together with relevant laboratory findings. The incidence will be calculated as the number of participants diagnosed with postoperative gut microbiota dysbiosis divided by the total number of participants evaluated in each treatment group, expressed as a percentage.

Postoperative days 1-5

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Changes in Gut Microbiota Composition and Diversity
Periodo de tiempo: Preoperatively and on postoperative days 3 and 5

Changes in gut microbiota composition and diversity will be assessed using metagenomic sequencing of fecal samples collected before surgery and during the postoperative period. Gut microbiota composition will be evaluated based on changes in microbial community structure and the relative abundance of bacterial taxa, while microbial diversity will be assessed using diversity indices derived from sequencing data. Changes in gut microbiota composition and diversity will be compared among the three treatment groups.

Preoperatively and on postoperative days 3 and 5
Changes in the Bifidobacterium-to-Escherichia coli Ratio (B/E Ratio)
Periodo de tiempo: Preoperatively and on postoperative days 3 and 5

The Bifidobacterium-to-Escherichia coli ratio (B/E ratio) in fecal samples will be assessed using gut microbiota sequencing data. Changes in the B/E ratio will be compared among the three treatment groups to evaluate alterations in intestinal microbial balance following surgery.

Preoperatively and on postoperative days 3 and 5
Serum C-Reactive Protein (CRP) Level
Periodo de tiempo: Preoperatively and on postoperative days 3 and 5

Serum C-reactive protein (CRP) levels will be measured to assess postoperative inflammatory responses. CRP concentrations will be compared among the three treatment groups. Results will be reported in mg/L.

Preoperatively and on postoperative days 3 and 5
Serum Procalcitonin (PCT) Level
Periodo de tiempo: Preoperatively and on postoperative days 3 and 5

Serum procalcitonin (PCT) levels will be measured as an indicator of postoperative inflammatory responses. PCT concentrations will be compared among the three treatment groups. Results will be reported in ng/mL.

Preoperatively and on postoperative days 3 and 5
Serum Interleukin-6 (IL-6) Level
Periodo de tiempo: Preoperatively and on postoperative days 3 and 5

Serum interleukin-6 (IL-6) levels will be measured to evaluate postoperative inflammatory responses. IL-6 concentrations will be compared among the three treatment groups. Results will be reported in pg/mL.

Preoperatively and on postoperative days 3 and 5
Fecal Short-Chain Fatty Acid (SCFA) Levels
Periodo de tiempo: Preoperatively and on postoperative days 3 and 5

Fecal concentrations of short-chain fatty acids (SCFAs), including acetate, propionate, and butyrate, will be measured to assess gut microbial metabolic activity. Changes in individual SCFA concentrations before and after surgery will be compared among the three treatment groups.

Preoperatively and on postoperative days 3 and 5

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Estimado)

20 de noviembre de 2026

Finalización primaria (Estimado)

31 de diciembre de 2027

Finalización del estudio (Estimado)

30 de junio de 2028

Fechas de registro del estudio

Enviado por primera vez

14 de noviembre de 2026

Primero enviado que cumplió con los criterios de control de calidad

14 de noviembre de 2026

Publicado por primera vez (Actual)

20 de noviembre de 2026

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

20 de noviembre de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

14 de noviembre de 2026

Última verificación

1 de noviembre de 2026

Más información

Términos relacionados con este estudio

Plan de datos de participantes individuales (IPD)

¿Planea compartir datos de participantes individuales (IPD)?

NO

Descripción del plan IPD

Individual participant data will not be shared with other researchers due to participant privacy and confidentiality considerations and the absence of an approved data-sharing plan.

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

No

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .

Suscribir